SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
A phase 3 trial testing Safusidenib in glioma & glioblastoma, now recruiting.
Overview
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance) is a phase 3 interventional study registered as NCT05303519, led by Nuvation Bio with AnHeart Therapeutics, and recruiting when checked on 2026-09-11. Official title: A Phase 3, Multicenter, Clinical Study to Evaluate the Efficacy and Safety of Safusidenib Erbumine in Participants With Isocitrate Dehydrogenase 1 (IDH1)-Mutant Glioma. Planned enrolment is 365 participants (estimated). The study started in 2023-06-05 and primary completion is expected in 2028-12-01. No results have been posted on ClinicalTrials.gov.
Similar pages
not linked directly; found by shared links- TrialStudy to Evaluate the Safety and Efficacy of ASC40 Tablets in Combination With Bevacizumab in Subjects With rGBM
Shares Glioma & glioblastoma and the tag ctgov-ingest.
- TrialLAM561 With RT and TMZ for Adults With Glioblastoma
Shares Glioma & glioblastoma and the tag ctgov-ingest.
- TreatmentINO-5401
Shares Glioma & glioblastoma and the tag ctgov-ingest.
- TreatmentBCB-276
Shares Glioma & glioblastoma and the tag ctgov-ingest.
- TreatmentASC40
Shares Glioma & glioblastoma and the tag ctgov-ingest.
- TreatmentTNG456
Shares Glioma & glioblastoma and the tag ctgov-ingest.
- TreatmentLAM561
Shares Glioma & glioblastoma and the tag ctgov-ingest.
- TreatmentCobolimab
Shares Glioma & glioblastoma and the tag ctgov-ingest.